Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
Profitability Metrics
Gross Margin
28.63%
Operating Margin
11.48%
Net Margin
6.57%
Efficiency Metrics
Revenue per Expense Ratio
1.13
R&D as % of Revenue
2.89%
Earnings Quality
EBITDA Margin
15.85%
Income Tax Rate
31.21%
EPS
5.9900000000
Balance Sheet Analysis
Current Ratio
1.43
Cash Ratio
0.27
Working Capital
$757.60M
Debt to Equity
1.24
Debt to Assets
41.61%
Equity Ratio
33.50%
Cash Flow Analysis
Operating Cash Flow Ratio
11.46%
Free Cash Flow Ratio
6.94%
CapEx to Revenue
4.52%
Dividends Paid
$112.00M
Stock Buybacks
$275.00M
Total Shareholder Returns
$387.00M
Cash Position Change
-23.12%
Key Takeaways (2023 FY)
Revenue declined by 6.030357300138%, indicating potential market challenges
Increased dividend payments by 9.89%
Detailed Growth Metrics
Core Performance
Revenue
-6.03%
Net Income
-37.90%
EPS
-33.81%
Operating Income
-22.46%
Operational Efficiency
R&D Expenses
-8.72%
SG&A Expenses
5.29%
Operating Cash Flow
25.17%
Free Cash Flow
124.62%
Balance Sheet Health
Assets
-1.44%
Debt
3.33%
Book Value per Share
8.91%
Inventory
0.37%
Shareholder Returns
Dividends per Share
9.89%
Shares Outstanding
-6.15%
Long Term Trends
3Y Revenue/Share
66.12%
5Y Revenue/Share
54.83%
3Y Dividend/Share
61.38%
5Y Dividend/Share
106.14%